聚乙二醇干扰素抗病毒治疗中的自身免疫性甲状腺炎

J. Roh, J. Yoo, Yoonbum Lee, H. An, H. Choi, K. T. Jung, J. Park, Kwan Sik Lee, K. Kim
{"title":"聚乙二醇干扰素抗病毒治疗中的自身免疫性甲状腺炎","authors":"J. Roh, J. Yoo, Yoonbum Lee, H. An, H. Choi, K. T. Jung, J. Park, Kwan Sik Lee, K. Kim","doi":"10.3803/JKES.2010.25.1.68","DOIUrl":null,"url":null,"abstract":"Combination treatment with pegylated interferon and ribavirin has been established as a standard therapy for chronic hepatitis C. Although interferon therapy is relatively safe, an important side effect is the induction of autoantibodies and autoimmune disease, especially autoimmune thyroid disease. Interferon associated autoimmune thyroid disease can consist of autoimmune hypothyroidism, Graves’ disease, and destructive thyroiditis. Thyroid disease may lead to dose reduction or discontinuation of therapy. To the best of our knowledge, there are no case reports of pegylated interferon induced autoimmune hypothyroidism in Korea. We report here a case of a 26-year-old woman who developed hypothyroidism during antiviral therapy for chronic hepatitis C with pegylated interferon. (J Korean Endocr Soc 25:68~71, 2010)","PeriodicalId":119859,"journal":{"name":"Journal of Korean Endocrine Society","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2010-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Autoimmune Thyroiditis during Antiviral Therapy with Peginterferon\",\"authors\":\"J. Roh, J. Yoo, Yoonbum Lee, H. An, H. Choi, K. T. Jung, J. Park, Kwan Sik Lee, K. Kim\",\"doi\":\"10.3803/JKES.2010.25.1.68\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Combination treatment with pegylated interferon and ribavirin has been established as a standard therapy for chronic hepatitis C. Although interferon therapy is relatively safe, an important side effect is the induction of autoantibodies and autoimmune disease, especially autoimmune thyroid disease. Interferon associated autoimmune thyroid disease can consist of autoimmune hypothyroidism, Graves’ disease, and destructive thyroiditis. Thyroid disease may lead to dose reduction or discontinuation of therapy. To the best of our knowledge, there are no case reports of pegylated interferon induced autoimmune hypothyroidism in Korea. We report here a case of a 26-year-old woman who developed hypothyroidism during antiviral therapy for chronic hepatitis C with pegylated interferon. (J Korean Endocr Soc 25:68~71, 2010)\",\"PeriodicalId\":119859,\"journal\":{\"name\":\"Journal of Korean Endocrine Society\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2010-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Korean Endocrine Society\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3803/JKES.2010.25.1.68\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Korean Endocrine Society","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3803/JKES.2010.25.1.68","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

聚乙二醇化干扰素和利巴韦林联合治疗已被确定为慢性丙型肝炎的标准治疗方法。尽管干扰素治疗相对安全,但一个重要的副作用是诱导自身抗体和自身免疫性疾病,特别是自身免疫性甲状腺疾病。干扰素相关的自身免疫性甲状腺疾病包括自身免疫性甲状腺功能减退、格雷夫斯病和破坏性甲状腺炎。甲状腺疾病可能导致剂量减少或停止治疗。据我们所知,在韩国没有聚乙二醇化干扰素引起自身免疫性甲状腺功能减退的病例报告。我们在此报告一例26岁的妇女谁发展甲状腺功能减退在抗病毒治疗慢性丙型肝炎与聚乙二醇化干扰素。(韩国医师学报25:68~71,2010)
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Autoimmune Thyroiditis during Antiviral Therapy with Peginterferon
Combination treatment with pegylated interferon and ribavirin has been established as a standard therapy for chronic hepatitis C. Although interferon therapy is relatively safe, an important side effect is the induction of autoantibodies and autoimmune disease, especially autoimmune thyroid disease. Interferon associated autoimmune thyroid disease can consist of autoimmune hypothyroidism, Graves’ disease, and destructive thyroiditis. Thyroid disease may lead to dose reduction or discontinuation of therapy. To the best of our knowledge, there are no case reports of pegylated interferon induced autoimmune hypothyroidism in Korea. We report here a case of a 26-year-old woman who developed hypothyroidism during antiviral therapy for chronic hepatitis C with pegylated interferon. (J Korean Endocr Soc 25:68~71, 2010)
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信